CommercialCoverageLow impact
Docetaxel (CPB 0956, reviewed 2026-10-05)
Aetna·Oncology, Hematology·Medical Policy
We identified it
Oct 8, 2026
Summary
This is a review of Aetna's existing Clinical Policy Bulletin 0956 for Docetaxel, last reviewed on 2026-10-05. The policy document confirms coverage criteria for docetaxel across multiple cancer indications (breast, lung, prostate, gastric, head/neck, ovarian, and others) for commercial medical plans. No change to the policy itself is documented; this is a policy restatement or routine review maintenance.
Action Required
No immediate action required. This document represents a policy review dated 2026-10-05 with no stated effective date for new changes. Verify that the practice's current billing system and prior authorization workflows already align with Aetna's documented coverage criteria for docetaxel (HCPCS codes J9171, J9172, J9174, J9232) across the listed cancer indications. If the practice bills for docetaxel administration (CPT 96413-96415), confirm that claims are submitted with appropriate cancer diagnosis codes (ICD-10 C-codes listed) and that prior authorization is obtained when required by the plan. No transition deadline or mandatory update is stated in the source.